Select a medication above to begin.
Oriahnn
elagolix/ estradiol/ norethindrone acetate and elagolix
Black Box Warnings .
Thromboembolic Disorders and Vascular Events
estrogen + progestogen tx incr. thrombotic/thromboembolism risk including PE, DVT, stroke, and MI, especially patients at high risk for these events; contraindicated in patients with current or past history of thrombotic/thromboembolic disorder or if incr. risk, including smokers >35 yo and uncontrolled HTN
Adult Dosing .
Dosage forms: CAP (pack): elagolix/estradiol/norethindrone acetate 300 mg/1 mg/0.5 mg x28 and elagolix 300 mg x28
heavy menstrual bleeding, uterine fibroid-associated
- [elagolix/estradiol/norethindrone 300 mg/1 mg/0.5 mg PO qam and elagolix 300 mg PO qpm]
- Start: after pregnancy excluded or within 7 days from onset of menses; Max: 24mo; Info: for premenopausal patients
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [see below]
- hepatic impairment/disease: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.